Table 2 Neurometabolites, spectral quality, and tissue fraction.

From: Neurometabolic correlates of 6 and 16 weeks of treatment with risperidone in medication-naive first-episode psychosis patients

 

HC

FEP

F/t

p

Neurometabolitesa

Baseline

NAA

0.38 (0.05)

0.37 (0.06)

0.29

0.77

Glx

0.22 (0.05)

0.22 (0.06)

0.08

0.94

Cho

0.16 (0.03)

0.17 (0.04)

−0.1

0.92

Cr

0.28 (0.06)

0.28 (0.08)

−0.25

0.80

Week 6

NAA

0.39 (0.04)

0.37 (0.03)

1.05

0.30

Glx

0.23 (0.05)

0.22 (0.03)

0.66

0.52

Cho

0.16 (0.02)

0.17 (0.03)

−0.94

0.35

Cr

0.28 (0.06)

0.29 (0.04)

−0.43

0.67

Week 16

NAA

0.39 (0.04)

0.39 (0.04)

−0.18

0.86

Glx

0.22 (0.07)

0.23 (0.03)

−0.53

0.60

Cho

0.17 (0.03)

0.18 (0.02)

−1.19

0.24

Cr

0.29 (0.05)

0.30 (0.06)

−0.23

0.82

Spectral quality indices

Baseline

NAA CRLB

1.50 (0.20)

1.70 (0.44)

−1.88

0.07

Glx CRLB

9.16 (1.70)

10.44 (3.07)

−1.61

0.12

Cho CRLB

2.77 (0.45)

3.24 (1.41)

−1.40

0.18

Cr CRLB

1.77 (0.28)

2.01 (0.71)

−1.31

0.20

FWHM

6.46 (2.16)

6.86 (1.59)

−0.66

0.52

SNR

15.18 (2.31)

13.72 (3.73)

−1.46

0.15

Week 6

NAA CRLB

1.54 (0.30)

1.55 (0.22)

−0.21

0.84

Glx CRLB

10.16 (3.47)

9.02 (1.86)

1.21

0.24

Cho CRLB

2.87 (0.55)

2.68 (0.34)

1.12

0.27

Cr CRLB

1.84 (0.40)

1.88 (0.63)

−0.27

0.79

FWHM

7.60 (1.96)

6.49 (1.00)

2.15

0.04

SNR

16.09 (2.35)

14.37 (1.42)

2.67

0.01

Week 16

NAA CRLB

1.54 (0.23)

1.56 (0.27)

−0.27

0.79

Glx CRLB

10.90 (3.56)

9.81 (2.40)

1.00

0.33

Cho CRLB

2.83 (0.30)

2.95 (1.25)

−0.34

0.73

Cr CRLB

1.79 (0.24)

2.04 (1.46)

−0.64

0.53

FWHM

7.99 (2.55)

7.50 (1.63)

0.63

0.53

SNR

16.09 (3.17)

15.39 (2.01)

0.74

0.47

Voxel tissue fraction

Baseline

Gray matter (%)

74.35 (5.59)

75.88 (3.88)

−1.01

0.32

White matter (%)

11.08 (7.71)

9.74 (3.49)

0.71

0.48

CSF (%)

14.78 (3.17)

13.85 (2.90)

0.97

0.34

Week 6

Gray matter (%)

76.25 (2.81)

75.45 (2.84)

0.84

0.41

White matter (%)

9.07 (2.57)

9.16 (2.36)

−0.11

0.91

CSF (%)

14.82 (2.72)

15.45 (3.07)

−0.64

0.53

Week 16

Gray matter (%)

75.30 (2.95)

76.18 (4.05)

−0.69

0.49

White matter (%)

10.58 (3.24)

9.07 (2.38)

1.52

0.14

CSF (%)

14.00 (2.15)

14.21 (3.59)

−0.23

0.82

  1. HC healthy control, FEP first-episode psychosis patient, NAA N-acetyl-aspartate, Glx glutamate + glutamine, Cho choline, Cr creatine, CRLB Cramer–Rao lower bounds, FWHM full width half maximum, SNR signal-to-noise ratio, CSF cerebrospinal fluid.
  2. aInstitutional units.
Back to article page